Nektar Therapeutics (NKTR) 14.92 $NKTR Pre-market Equity

New Post Public Reply Private Reply Replies (0) Message Board

Jul 11, 2016 at 3:08 AM

Nektar Therapeutics (NKTR) 14.92 $NKTR

Pre-market Equity Watch on Biotechnology -- Infinity Pharma, Nektar Therapeutics, Aralez Pharma, and BIND Therapeutics
PR Newswire - Thu Jun 23, 7:20AM CDT
On Wednesday, June 22, 2016, the NASDAQ Composite ended the trading session at 4,833.32, down 0.22%; the Dow Jones Industrial Average edged 0.27% lower to finish at 17,780.83; and the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following equities: Infinity Pharmaceuticals Inc. (NASDAQ: INFI), Nektar Therapeutics (NASDAQ: NKTR), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ), and BIND Therapeutics Inc. (NASDAQ: BIND). Learn more about these stocks by accessing their free trade alerts at:
BIND: 0.56 (+0.01), ARLZ: 3.61 (+0.05), INFI: 1.40 (+0.08), NKTR: 14.92 (+0.62)

Preclinical Data Presented at ASCO 2016 Annual Meeting Demonstrate that Single-Agent NKTR-214 Produces a Large Increase in Tumor-Infiltrating Lymphocytes to Provide Durable Anti-Tumor Activity
PR Newswire - Mon Jun 06, 1:00PM CDT
Nektar Therapeutics (NASDAQ: NKTR) today announced new preclinical data for NKTR-214, an immuno-stimulatory CD-122 biased cytokine currently being evaluated in cancer patients with solid tumors in a Phase 1/2 clinical trial being conducted at MD Anderson Cancer Center and Yale Cancer Center. The new preclinical data presented demonstrate that treatment with single-agent NKTR-214 mobilizes tumor-killing T cells into colon cancer tumors. In addition, mouse pharmacodynamics data demonstrated that a single dose of NKTR-214 can increase and sustain STAT5 phosphorylation (a marker of IL-2 pathway activation) through one week post-dose. These data were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL from June 3-7, 2016.
NKTR: 14.92 (+0.62)

Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the Jefferies 2016 Global Healthcare Conference in New York City
PR Newswire - Thu Jun 02, 5:30PM CDT
Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming Jefferies 2016 Global Healthcare Conference in New York City on Wednesday, June 8, 2016 at 11:30 a.m. Eastern time.
NKTR: 14.92 (+0.62)

Nektar Therapeutics Announces Executive Management Promotions
PR Newswire - Thu Jun 02, 3:30PM CDT
Nektar Therapeutics (NASDAQ: NKTR) announced today that John Nicholson has been named Senior Vice President & Chief Operating Officer and Gil M. Labrucherie has been named Senior Vice President & Chief Financial Officer of Nektar. Mr. Nicholson has served as the Chief Financial Officer of Nektar since 2007. Mr. Labrucherie has served as Senior Vice President, General Counsel and Secretary of Nektar since 2007.
NKTR: 14.92 (+0.62)

Nektar (NKTR) Inks Deal With Daiichi Sankyo for Onzeald
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 7:37AM CDT
Nektar Therapeutics (NKTR) has entered an agreement to grant Daiichi Sankyo Europe the exclusive rights to market Onzeald in Europe, Switzerland and Turkey.
ANIP: 56.51 (-1.61), PFE: 36.12 (+0.35), BMY: 75.28 (+1.20), NKTR: 14.92 (+0.62)

Nektar Therapeutics and Daiichi Sankyo Europe GmbH Sign European Licensing Agreement for ONZEALD(TM) (etirinotecan pegol), an Investigational Drug Candidate Being Developed to Treat Patients with Advanced Breast Cancer and Brain Metastases
PR Newswire - Wed Jun 01, 7:15AM CDT
Nektar Therapeutics (Nasdaq: NKTR) today announced that it has entered into an agreement with Daiichi Sankyo Europe for Nektar's investigational drug therapy, ONZEALD (etirinotecan pegol, NKTR-102), which has completed a Phase 3 clinical trial (the BEACON study) in patients with advanced breast cancer. The agreement grants Daiichi Sankyo Europe exclusive rights to market ONZEALD in Europe (EEA), Switzerland and Turkey. Nektar Therapeutics will retain rights to ONZEALD in the United States and the rest of the world.
NKTR: 14.92 (+0.62)

Neos Therapeutics Appoints Juergen Martens as Chief Technology and Operations Officer
GlobeNewswire - Tue May 31, 3:05PM CDT
Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing and commercializing innovative extended-release (XR) products for the treatment of attention-deficit/hyperactivity disorder (ADHD), today announced that it has appointed Juergen A. Martens, PhD, to the position of Chief Technology and Operations Officer.
NKTR: 14.92 (+0.62), NEOS: 9.37 (+0.25)

AWS Morning Technical Breakdown Highlights: bluebird bio, Nektar Therapeutics, Sequenom, and Tesaro
ACCESSWIRE - Mon May 23, 8:18AM CDT
LONDON, UK / ACCESSWIRE / May 23, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include bluebird bio, Nektar Therapeutics, Sequenom, and Tesaro.
BLUE: 48.75 (-0.08), SQNM: 0.92 (+0.03), TSRO: 88.70 (-3.26), NKTR: 14.92 (+0.62)

Avalanche (AAVL) Reports Wider-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Mon May 09, 9:16AM CDT
Avalanche Biotechnologies, Inc. (AAVL) reported a loss of 57 cents per share in the first quarter of 2016,.
SHPG: 188.21 (-1.31), AAVL: 4.14 (-0.18), NKTR: 14.92 (+0.62), REGN: 378.35 (+6.90)

Intercept (ICPT) Q1 Loss Narrower than Expected, Sales Lag
Zacks Equity Research - Zacks Investment Research - Fri May 06, 2:59PM CDT
Intercept Pharmaceuticals, Inc. (ICPT) posted a loss of $3.33 per share in the first quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of $3.58 but wider than the year-ago loss of $1.78.
SHPG: 188.21 (-1.31), ICPT: 151.73 (+7.98), BIOD: 0.31 (-0.01), NKTR: 14.92 (+0.62)

Radius Health (RDUS) Reports Wider-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Fri May 06, 2:54PM CDT
Radius Health, Inc. (RDUS) posted a loss of 94 cents per share in the first quarter of 2016, wider than both the Zacks Consensus Estimate of a loss of 83 cents and the year-ago loss of 47 cents
RDUS: 41.25 (+0.77), SHPG: 188.21 (-1.31), BIOD: 0.31 (-0.01), NKTR: 14.92 (+0.62)

Endocyte (ECYT) Reports Narrower than Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Thu May 05, 3:01PM CDT
Endocyte, Inc. (ECYT) reported a first-quarter 2016 loss of 24 cents per share, narrower than both the Zacks Consensus Estimate of a loss of 26 cents and the year-ago loss of 26 cents.
MNK: 62.29 (+0.82), ECYT: 3.21 (+0.04), SHPG: 188.21 (-1.31), NKTR: 14.92 (+0.62)

McKesson (MCK) Q4 Earnings Lag, Revenues Top Marginally
Zacks Equity Research - Zacks Investment Research - Thu May 05, 2:58PM CDT
McKesson Corporation (MCK) reported fourth-quarter fiscal 2016 (ended Mar 31, 2016) earnings of $2.44 per share, lower than both the Zacks Consensus Estimate of $3.01 and the year-ago figure of $2.94.
MCK: 192.79 (+1.59), SHPG: 188.21 (-1.31), NKTR: 14.92 (+0.62), RAD: 7.10 (-0.19)

Why Nektar Therapeutics Inc Is Dropping Today
Brian Feroldi, The Motley Fool - Motley Fool - Wed May 04, 3:53PM CDT
Image source: Images_of_Money via Flickr Creative Commons. What: Shareholders of Nektar Therapeutics are having a bit of a rough day; the company's stock has dropped more than 10% as of 3:45 p.m. ET today after investors got a good look at the...
AZN: 30.11 (unch), BXLT: 46.02 (-0.18), NKTR: 14.92 (+0.62)

Nektar (NKTR) Reports Narrower-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Wed May 04, 2:06PM CDT
Nektar (NKTR) reported a narrower-than-expected loss of 14 cents in the first quarter on revenues of $58.9 million.
OMED: 13.01 (+0.15), AZN: 30.11 (unch), BXLT: 46.02 (-0.18), NKTR: 14.92 (+0.62)

Nektar Therapeutics Has Returned 9.6% Since SmarTrend Recommendation (NKTR)
Comtex SmarTrend(R) - Wed May 04, 1:50PM CDT
SmarTrend identified an Uptrend for Nektar Therapeutics (NASDAQ:NKTR) on March 11th, 2016 at $12.56. In approximately 2 months, Nektar Therapeutics has returned 9.60% as of today's recent price of $13.76.
NKTR: 14.92 (+0.62)

Prothena (PRTA) Reports Wider-than-Expected Loss in Q1
Zacks Equity Research - Zacks Investment Research - Wed May 04, 12:00PM CDT
Prothena Corporation plc (PRTA) reported a loss of 81 cents per share in the first quarter of 2016, much wider than both the Zacks Consensus Estimate of a loss of 70 cents.
SHPG: 188.21 (-1.31), PRTA: 44.01 (+2.28), NKTR: 14.92 (+0.62)

Nektar Therapeutics Reports Financial Results for the First Quarter of 2016
PR Newswire - Tue May 03, 3:05PM CDT
Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2016.
NKTR: 14.92 (+0.62)

Nektar to Announce Financial Results for the First Quarter 2016 on Tuesday, May 3, 2016, After Close of U.S.-Based Financial Markets
PR Newswire - Thu Apr 28, 7:00AM CDT
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2016, on Tuesday, May 3, 2016, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 4:30 p.m. Eastern Time (ET)/1:30 p.m. Pacific Time (PT).
NKTR: 14.92 (+0.62)

29.9% Return Seen to Date on SmarTrend Nektar Therapeutics Call (NKTR)
Comtex SmarTrend(R) - Wed Apr 27, 1:32PM CDT
SmarTrend identified an Uptrend for Nektar Therapeutics (NASDAQ:NKTR) on March 11th, 2016 at $12.56. In approximately 2 months, Nektar Therapeutics has returned 29.87% as of today's recent price of $16.31.
NKTR: 14.92 (+0.62)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lincoln Educational Faces Investor Lawsuit Over Revenue Drop

Investors Face Rough Waters Okay, let’s dive into this latest mess at Lincoln Educational Services Corp. (NASDAQ:LINC). Things aren't smelling too rosy over at their headquarters. If you've got shares here, you’ll know what I mean. Back in early May, the folks running Lincoln threw a garden party talking up a 19.5% growth in student starts. Who wouldn’t get behind...

Medicare Limits and Long-Term Care Planning Tips

Grappling with Medicare's Gaps Most folks hear Medicare and feel a sigh of relief—thinking it's a catch-all net for healthcare in your golden years. But hold on, when it comes to long-term care, Medicare's got more holes than Swiss cheese. Cindy Couyoumjian from Cinergy Financial lays it out pretty clear: Medicare doesn't cover what it calls 'custodial care'—you know,...

PZZA Faces Class Action: Strategic Shake-up or Misstep?

Papa John's: Doughy Deceit or Strategic Misfire? Once in a while, a corporation trips over its own ambitious production line, and Papa John’s (NASDAQ:PZZA) is the latest contestant to make headlines for all the wrong reasons. Investors in this pizza powerhouse are being called to the courtroom as a class action lawsuit unfolds, marking a turbulent stage in the...

Amy Johnson Steps Up as GDIT President Amid Shifts

A New Chapter for GDIT with a Veteran Leader Big shoes to fill? Nah, more like Amy Johnson was made for these shoes. Stepping up as president of General Dynamics Information Technology (GDIT) on November 3, she’s got 27 years of experience under her belt, all from General Dynamics' own backyard. This ain't her first rodeo. From tightrope-walking the perils of defense...

Shanghai and Hamburg Celebrate 40 Years of Collaboration

Strengthening the Bond: A Four-Decade Journey With fireworks of diplomacy and cooperation lighting up, Shanghai and Hamburg marked the 40th anniversary of their friendship with an ambition to deepen and broaden ties. These cities, separated by continents but united by their maritime spirit, decided to toast not just the past but also the future. This isn't just some fancy...

FDA Nod for Subcutaneous SKYRIZI in Crohn's Disease

AbbVie's Injection Makes Waves in Crohn's Treatment Here's a bit of medicine shake-up for you. AbbVie just snagged FDA approval for its subcutaneous SKYRIZI—specifically designed for adults battling moderately to severely active Crohn's disease. This news isn't just a blip on the radar; it's significant for patients and the healthcare landscape. We're talking about new...

Dimora Medical Boosts Advanced Wound Care at HS Conference

Empowering the HS Community with Innovations Look, if you’ve walked a mile in someone else's shoes—particularly ones dealing with hidradenitis suppurativa (HS)—you’d know what a relentless grind managing those exuding wounds can be. Dimora Medical, known for navigating the tricky territory of wound care, threw its hat into the ring at the HS Connect Empower...

Innventure Faces Chaotic Legal Storm Over DarkNX Scandal

Innventure's DarkNX Project: From Boon to Bane The stock market is no stranger to seismic shifts, but Innventure, Inc.'s recent plunge is a testament to the catastrophic impact missteps can unleash. This whole DarkNX debacle feels more like a meticulous car wreck than a business evolution. Unpacking the Allegations Sitting comfortably under the NASDAQ:INV ticker,...

Northern Virginia's Housing Inventory Surges Despite Market Pressures

Unexpected Surge in Northern Virginia's Inventory Walking around Fairfax these days, you might feel like you're in a time warp, especially if you're tracking the housing market. See, while the rest of the country's housing market groans under sluggish sales and creeping prices, Northern Virginia's doing a dance of its own. Inventory's ballooning faster than a parade...

Hexagon Composites to Release Q3 2026 Results Soon

Anticipating Hexagon's Third Quarter 2026 Results Hexagon Composites ASA, based out of Oslo, Norway, is setting the stage to release its third quarter 2026 financial results. Mark your calendars for November 6, 2026, at the early bird hour of 07:00 am CET. For those of us keen on dissecting the numbers, that's when the real action begins. Executive Insights Await A...